GlassScriptPhysician profile
Julius A Debroeck
NPI 1023180429
$8,750.86
in general payments reported to CMS, 2019-2025
62 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,808 · 2020: $2,032 · 2021: $1,479 · 2022: $1,143 · 2023: $1,480 · 2024: $687 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,289.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,075.39 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $925.91 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $741.72 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $657.02 | 2019-2025 | Jardiance |
| Pfizer INC. | $604.10 | 2019-2025 | |
| Lilly USA, LLC | $531.96 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $373.85 | 2019-2024 | Trintellix |
| Amgen INC. | $321.73 | 2019-2024 | Otezla, Repatha, Prolia |
| Allergan, INC. | $305.23 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $195.67 | 2020-2021 | |
| Abbott Laboratories | $172.24 | 2022-2024 | Freestyle Libre 3, Proclaim |
| Glaxosmithkline, LLC. | $155.36 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $150.81 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.99 | 2022-2024 | |
| Corium, LLC | $144.76 | 2022-2024 | Azstarys |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Debroeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.